What is SimBioSys?
SimBioSys is a pioneering technology firm that integrates artificial intelligence with biophysical simulations to deepen the medical community's understanding of cancer. Its flagship engine, TumorScope, transforms standard diagnostic data—such as imaging and pathology—into spatially resolved virtual replicas of a patient's tumor and its surrounding microenvironment. By utilizing mechanistic models to simulate drug sensitivity, metabolism, and mechanical forces, the company provides clinicians with a comprehensive view of disease progression and resistance mechanisms.
Unlike traditional genomic-focused approaches, SimBioSys offers a unique value proposition by relying on readily available datasets to enhance treatment personalization. This methodology allows for the computational assessment of therapeutic options, effectively empowering researchers and clinicians to make more informed, data-driven decisions in the fight against cancer.
How much funding has SimBioSys raised?
SimBioSys has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2021): $15M with participation from Mayo Clinic, Heritage Medical Group, Northpond Ventures, Genoa Ventures, and AV8 Ventures
Key Investors in SimBioSys
Mayo Clinic
Mayo Clinic is a nonprofit global healthcare organization specializing in integrated clinical practice, education, and medical research, bringing together specialists to address complex health conditions.
Genoa Ventures
Genoa Ventures is an investment firm focused on early-stage companies that are innovating at the intersection of biology and technology, aiming to accelerate innovation in bioconvergence.
AV8 Ventures
AV8 Ventures is an investment firm that supports early-stage start-ups in sectors such as healthcare, enterprise, and deep-tech, partnering with founders to build category-defining companies.
What's next for SimBioSys?
With this major enterprise-level funding, SimBioSys is poised to accelerate the integration of its simulation technology into standard clinical workflows. The strategic roadmap likely involves deepening partnerships with major healthcare institutions to validate the efficacy of TumorScope across diverse patient populations. By focusing on the intersection of bioconvergence and clinical decision support, the company is set to challenge existing paradigms in oncology, potentially reducing the barriers to adoption for digital health solutions. Future growth will likely center on expanding the platform's predictive capabilities and securing further regulatory milestones to solidify its position as a leader in the precision oncology market.
See full SimBioSys company page
